These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541 [TBL] [Abstract][Full Text] [Related]
6. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869 [TBL] [Abstract][Full Text] [Related]
7. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF mBio; 2019 Dec; 10(6):. PubMed ID: 31848282 [TBL] [Abstract][Full Text] [Related]
8. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells. Richard J; Nguyen DN; Tolbert WD; Gasser R; Ding S; Vézina D; Yu Gong S; Prévost J; Gendron-Lepage G; Medjahed H; Gottumukkala S; Finzi A; Pazgier M mBio; 2021 Oct; 12(5):e0140521. PubMed ID: 34579568 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir. Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173 [TBL] [Abstract][Full Text] [Related]
11. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448 [TBL] [Abstract][Full Text] [Related]
12. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574 [TBL] [Abstract][Full Text] [Related]
15. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques. Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963 [TBL] [Abstract][Full Text] [Related]
16. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. McGuire AT; Glenn JA; Lippy A; Stamatatos L J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455 [TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D; Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566 [TBL] [Abstract][Full Text] [Related]
18. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842 [TBL] [Abstract][Full Text] [Related]